Infection and cancer

For a long time, it was thought that cancer and infections were two completely unrelated diseases - and that view is still going strong. After all, infectious diseases are those you contract; cancer develops within the body itself. Now, three of the more common cancers - stomach, liver, and cervical - have shown that this notion has been proven wrong.  

Cervical cancer is the result of exposure to HPV, human papilloma virus. Infection with hepatitis virus is the culprit behind nearly 80 percent of all hepatic cancers. And some 75 percent of stomach tumors can be traced back to exposure to Helicobacter pylori.  

And that's just the tip of the iceberg: Worldwide, some 14 million people develop cancers annually - a high percentage of those diseases are caused by pathogens like viruses or bacteria. And, of course, cancer patients in general are particularly susceptible to infection. By extension, then, infection research is cancer research - and vice versa.

Joining forces against hepatitis C viruses

Scientists at the HZI subsidiary TWINCORE are investigating the mechanisms hepatitis C virus uses to proliferate in the liver. Roughly 130 million people worldwide have chronic hepatitis C and are living with the risk of developing hepatic cancer at some point down the line. Along with their TWINCORE and HIPS colleagues, HZI researchers are searching for potential new drugs capable of interfering with viral proliferation. Preliminary cancer therapy if you will.

Epothilon - the basic ingredient of a new cancer drug - interferes with tumor cell division inside the nucleus by blocking the spindle apparatus and thus the segregation of the genetic material (shown in blue) into two equal parts.

Jack-of-all-trades: natural substances

Epothilon is a natural substance HZI scientists have managed to isolate from soil bacteria in their search for effective substances and which was subsequently developed into a drug for breast cancer and approved for use in the US back in 2007.  

The search for new active substances from Nature provides a focal point for the research that is currently happening at the HZI - the scientists' special focus is on identifying new antiinfectives.

Infections against cancer

Yet infections and cancers have common points of contact in other respects as well. As such, HZI scientists are working on using bacteria to fight tumors. They are using salmonella to colonise and kill off the tumor and at this point have already scored several major successes treating tumors in mice. Salmonella-based cancer treatment is still a far cry from human application - the pathogen is far too virulent and the risk of killing off the tumor while inadvertently triggering a serious salmonellosis is far too great.

(Dr Jan Grabowski)

Video Podcast

  • Epothilon: Ein HZI-Molekül wird zum Krebsmedikament
    Wissenschaftler an der ehemaligen Gesellschaft für Biotechnologische Forschung (GBF), dem heutigen HZI, haben in den 1980er Jahren Epothilon B entdeckt. Dieser Naturstoff stört die Teilung von Krebszellen: Tumore werden durch ihn im Wachstum gebremst, schrumpfen und verschwinden. Das Pharmaunternehmen Bristol-Myers Squibb (BMS) hat jetzt auf der Basis von Epothilon B ein Krebsmedikament auf den US-amerikanischen Markt gebracht. Seine Entwicklung ist so spannend wie ein Krimi...
    Länge: 11:34

Audio Podcast

  • Der Wächter gegen Krebs: Botenstoffe des Immunsystems hemmen das Krebswachstum
    Interferone durchströmen uns, wenn wir von Viren angegriffen werden oder eine schwere Entzündung haben. Sie sorgen – neben der Abwehr – dafür, dass wir uns krank fühlen. Aber sie hungern außerdem mit bislang ungeahnten Mechanismen Tumore aus. Diese Mechanismen könnten der Schlüssel zu neuen Therapie-Ansätzen gegen Krebs sein. Jadwiga Jablonska erklärt Ihnen, was Interferon in Tumoren auslöst…
  • Salmonellen gegen Krebs
    Salmonellen haftet ein schlechtes Image an – prinzipiell zu Recht. Kaum ein Jahr vergeht ohne Meldung von Salmonellen-Infektionen in den Zeitungen. Aber wie (fast) alles, haben auch Salmonellen zwei Seiten: Sie machen nicht nur krank, sondern sammeln sich auch in Tumoren, finden auf eigene Faust Metastasen und töten diese ab. Hören Sie zu, wie Sara Bartels die Grundlagen für diese revolutionäre Therapieidee erforscht!


Research Groups